The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Abstract
The availability of L-arginine in tumours is a key determinant of an efficient anti-tumour T cell response 1-4. Consequently, increases of typically low L-arginine concentrations within the tumour may greatly potentiate the anti-tumour responses of immune checkpoint inhibitors, such as programmed death-ligand 1 (PD-L1)-blocking antibodies 5. However, currently no means are available to locally increase intratumoural L-arginine levels. Here we used a synthetic biology approach to develop an engineered probiotic Escherichia coli Nissle 1917 strain that colonizes tumours and continuously converts ammonia, a metabolic waste product that accumulates in tumours 6, to L-arginine. Colonization of tumours with these bacteria increased intratumoural L-arginine concentrations, increased the number of tumour-infiltrating T cells and had marked synergistic effects with PD-L1 blocking antibodies in the clearance of tumours. The anti-tumour effect of these bacteria was mediated by L-arginine and was dependent on T cells. These results show that engineered microbial therapies enable metabolic modulation of the tumour microenvironment leading to enhanced efficacy of immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intertumoral injection of this strain in mice increased the intracellular L-arginine concentration, triggered intratumoral CD4+ T cell and CD8+ T cell infiltration, and exerted synergistic antitumor effects when combined with anti-PD-L1 [154].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [154]
In the citing paper
“The engineered probiotic Escherichia coli Nissle 1917 strain colonizes tumor sites and continuously converts the metabolite ammonia to L-arginine in the tumor bed [154].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [154]
In the citing paper
“High levels of microbiota-derived arginine are associated with improved PFS in patients receiving ICIs. In murine tumor models, boosting L-arginine levels enhances the antitumor effects of ICIs in a T cell-dependent manner.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [45]
In the citing paper
“E. coli Nissle 1917 has also been engineered to generate higher levels of L-arginine, which metabolically reprograms TMEs and enhances the efficacy of ICI antitumor activity.45”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [45]
Citations
Cites
Cox, J., & Mann, M. (2008) · Nature Biotechnology · doi:10.1038/nbt.1511 · Cited by 14,855
Mass spectrometry-based proteomics
Aebersold, R., & Mann, M. (2003) · Nature · doi:10.1038/nature01511 · Cited by 6,955
Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., & Mann, M. (2011) · Journal of Proteome Research · doi:10.1021/pr101065j · Cited by 5,500
Rappsilber, J., Mann, M., & Ishihama, Y. (2007) · Nature Protocols · doi:10.1038/nprot.2007.261 · Cited by 4,641
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775
Self-citationEngineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Rodríguez, P. C., & Ochoa, A. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00608.x · Cited by 719
Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605
Self-citationMetabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass
Spinelli, J. B., Yoon, H., Ringel, A. E., Jeanfavre, S., Clish, C. B., & Haigis, M. C. (2017) · Science · doi:10.1126/science.aam9305 · Cited by 468
Research works printed but not linked: 1
- Malissen, M. et al. Altered T cell development in mice with a targeted mutation of the CD3-epsilon gene. EMBO J. 14, 4641-4653 (1995). · DOI · Paper page
Cited by
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies
Aggarwal, N., Kitano, S., Puah, G. R. Y., Kittelmann, S., Hwang, I. Y., & Chang, M. W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00431 · Cited by 508
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
(2022) · doi:10.1186/s13045-022-01273-9 · Cited by 495
Engineering bacteria as interactive cancer therapies
Gurbatri, C. R., Arpaia, N., & Danino, T. (2022) · Science · doi:10.1126/science.add9667 · Cited by 447
Metadata
- Authors
- Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., Theurillat, J.-P., West, K. A., Leventhal, D. S., Lora, J. M., Sallusto, F., & Geiger, R.
- Affiliations
- Institute for Research in Biomedicine (CH)
- Ente Ospedaliero Cantonale (CH)
- ETH Zurich (CH)
- Synlogic (United States) (US)
- Institute of Oncology Research (CH)
- Corresponding author
- Geiger, Roger
- ORCID
- Venue
- Nature
- Published
- 2021-10-06
- Volume
- 598
- Issue
- 7882
- Pages
- 662-666
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3174561819
- Cited by
- 619
- References
- 19
- Citations by year
- 2026: 117 · 2025: 167 · 2024: 146 · 2023: 109 · 2022: 72 · 2021: 8
- FWCI
- 44.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- engineered bacteria, Escherichia coli Nissle 1917, L-arginine, ammonia conversion, PD-L1 blockade, immune checkpoint inhibitors, tumor-infiltrating T cells, cancer immunotherapy, synthetic biology
- MeSH terms
- Microorganisms, Genetically-Modified, Animals, Arginine, Escherichia coli, Female, Immunotherapy, Mice, Inbred C57BL, Neoplasms, Experimental, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Mice, Knockout, Adoptive Transfer, Probiotics, Proteome, Cell Line, Tumor, Mice, Synthetic Biology, Tumor Microenvironment, Metabolic Engineering, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic modulation of tumours with engineered bacteria for immunotherapy. https://app.cochat.ai/papers/10.1038/s41586-021-04003-2
- The paper
- Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., Theurillat, J.-P., West, K. A., Leventhal, D. S., Lora, J. M., Sallusto, F., & Geiger, R. (2021). Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature. https://doi.org/10.1038/s41586-021-04003-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.